Alpha Stem Cell Clinics Trials

The Alpha Stem Cell Clinics Network is pursuing its goal to accelerate the development and delivery of stem cell treatments to patients through high quality clinical trials. 

Browse the list of ongoing trials at Alpha Stem Cell Clinic locations in the table below. You can sort trials based on different fields by clicking on the appropriate column header. Trials are automatically listed by status of trial enrollment and Alpha Clinic location.

Alpha Clinic Trials

Alpha ClinicAlpha Clinic ContactTrial SponsorDisease IndicationClinical Trial NameStatus of EnrollmentLearn More
UCSF and UC Davis
Julie DeCaris
510-428-3885. ext.2739
Julie.decaris@ucsf.edu

Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Bioverativ Therapeutics, Inc Sickle Cell Disease A Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients with Severe Sickle Cell Disease Recruiting
UCSF
Cyrus Bascon
510-428-3885 ext 6953
Cyrus.bascon@ucsf.edu
CIRM & NHLBI Severe sickle cell disease Transplantation of CRISPRCas9 Corrected Hematopoietic Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease Recruiting
UCSF
Kenny Truong, RN
415-502-2080
kenny.truong@ucsf.edu
Jasper Therapeutics Severe Combined Immunodeficiency syndrome A Phase 1 study to evaluate the safety and tolerability of tandemly-purified allogeneic CD34+CD90+ HSC administered following conditioning with JSP 191 to achieve engraftment and immune reconstitution in patients with SCID Recruiting
UCSF
Cyrus Bascon
510-428-3885 ext 6953
Cyrus.bascon@ucsf.edu
Editas Medicine Inc. Sickle Cell Disease A Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited CD34+ Human Hematopoietic Stem and Progenitor Cells (EDIT-301) in Subjects With Severe Sickle Cell D Recruiting
UCSF
Cyrus Bascon
510-428-3885 ext 6953
Cyrus.Bascon@ucsf.edu
Passage Bio Inc. GM1 Gangliosidosis A Phase 1/2 Open-Label, Multicenter, Dose Ranging and Confirmatory Study to Assess the Safety, Tolerability and Efficacy of a Single Dose of PBGM01 Delivered into the Cisterna Magna of Pediatric Subjects Aged 4 to 24 Months with Type 1 (Early Onset Infant Recruiting
UCSF Talaris Transplanted Organ Rejection A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation (FREEDOM-1) Recruiting
UCSF
Gabrielle Garcia
Gabriel.Garcia@ucsf.edu
Allo Vir, Inc. BK Viremia in Kidney Transplant Recipients Phase 2 study in patients with BK Viremia in Kidney Transplant Recipients Recruiting
UCSF
Marisa Gin
415-476-3816
Marissa.Gin@ucsf.edu
Poseida Therapeutics, Inc. Prostate cancer A Phase 1 Dose Escalation and Expanded Cohort Study of P‑PSMA‑101 in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) Recruiting
UCSF
Joseph Seo
415-514-4805
Joseph.Seo@ucsf.edu
Cellectis, SA Multiple Myeloma Phase I, open label dose‐escalation study to evaluate the safety, expansion, persistence and clinical activity of UCARTCS1A (allogeneic engineered T‐cells expressing anti‐CS1 chimeric antigen receptor), administered in patients with Relapsed/Refractory Mu Recruiting
UCSF
Allegra Koch
415-476-2381
Allegra.koch@ucsf.edu
CRISPR Therapeutics B Cell Malignancies Non-hodgkin Lymphoma, B-cell Lymphoma, Adult B Cell ALL A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9–Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B Cell Malignancies Recruiting
UCSF & UCSD & CIRM
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
CIRM ARDS/COVID Prospective, Randomized, Multi-center Phase 2 Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Recruiting
UCSF & UC Davis
Hanjing Zhou
415-502-7434
hanging.zhou@ucsf.edu
COVID-19/ARDS Mesenchymal Stromal Cells for ARDS (COVID positive and COVID negative) Recruiting
UCSF
Marisa Gin
415-476-3816
Marisa.gin@ucsf.edu
PACT Pharma Cancer – Solid Tumor A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors Recruiting
UCSF
Kenny Truong
(415) 502-2080
Kenny.Truong@ucsf.edu
UCSF Graft versus Host Disease (GvHD) An Expanded Access Study of Using the CLINIMACS® Device for Alpha/Beta T-Cell Depletion in Stem Cell Transplant Recipients Recruiting
UCSF
Rebecca Hoh
415.476.4082 ext. 139
Rebecca.Hoh@ucsf.edu
Case Western Reserve University HIV A Comparative Study of Autologous CD4+ T Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 versus ex vivo Expanded Unmodified Autologous CD4+ T Cells in Treated HIV-1 Infected Subjects (TRAILBLAZER) Recruiting
UCSF & UC Davis
Caleb Hwang
415-502-3498
Caleb.hwang@ucsf.edu

Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Poseida Therapeutics, Inc. Multiple Myeloma Open-Label, Multicenter, Single Ascending Dose Study to Assess the Safety of P-BCMA-101 in Subjects with Relapsed/Refractory Multiple Myeloma (MM) Followed by a Phase 2 Assessment of Response and Safety (PRIME) Active, not recruiting
UCSF
Hanjing Zhou
415-502-7434
hanging.zhou@ucsf.edu
Department of Defense Acute Respiratory Distress Syndrome (ARDS) A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial of Allogenic Bone Marrow-derived Human Mesenchymal Stromal Cells for the Treatment of Acute Respiratory Distress Syndrome After Trauma Recruiting
UCSF
Carol Fraser-Brown
415-476-2188
carol.fraser-browne@ucsf.edu
Stanford University Severe Combined Innunodeficiency (SCID) AMG191 Conditioning/CD34+CD90 Stem Cell Transplant Study for SCID Patients Recruiting
UCSF
Julie DeCaris
510-428-3885 ext 2739
jdecaris@mail.cho.org
Seattle Children’s Hospital Foundation Cancer - Leukemia A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia Recruiting
UCSF & UCLA
Marci Moriarty, BSN, RN
510-428-3885 ext 5396
mmoriarty@mail.cho.org

Bruck Habtemariam
310-794-0242
bhabtemariam@mednet.ucla.edu
Sangamo Therapeutics Blood Disorder - Beta-Thalassemia A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT) Recruiting
UCSF
Cyrus Bascon
510-428-3885 ext 5396
CBascon@mail.cho.org
bluebird bio Sickle Cell Disease A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in Severe Sickle Cell Disease Active, not recruiting
UCSF
Romobia Hutchinson
415-476-9326
romobia.hutchinson@ucsf.edu
UCSF Blood Disorder - Alpha Thalassemia Major In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM) Recruiting
UCSD UCSD & CIRM Cystinosis Stem cell gene therapy for cystinosis Recruiting
UCSD Tigenix Crohn's Disease Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn’s Disease (CD) Recruiting
UCSD Calibr Relapsed/Refractory B-cell Lymphomas Long term follow-up study for patients administered CLBR001 , a CAR-T cell Recruiting
UCSD Calibr Relapsed/Refractory B-cell Lymphomas CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies Recruiting
UCSD Fate Therapeutics Solid tumors FATE-NK100 as Monotherapy and in Combination with Monoclonal Antibody in Subjects with Advanced Solid Tumors Active, not recruiting
UCSD
Benjamin M Heyman, MD
858-246-3038
bheyman@ucsd.edu
UCSD/Oncternal chronic lymphocytic leukemia Cirmtuzumab Consolidation for Treatment of Patients with Detectable CLL on Venetoclax Recruiting
UCSD Aivita Ovarian and Fallopian Tube Carcinoma Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas Active, not recruiting
UCSD
Teresa Rzesiewicz
844-317-7836
alphstemcellclinic@ucsd.edu
Discgenics Degenerative Disc Disease Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration Active, not recruiting
UCSD
Barbara Parker, MD
858-822-6135
baparker@ucsd.edu

Rebecca Shatsky, MD
858-657-7000
rshatsky@ucsd.edu
UCSD Cancer - Breast Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer Active, not recruiting
UCSD Persimmune, Inc. Cancer - Blood Personalized Adoptive Cellular Therapy Targeting MDS Stem Cell Neoantigens (PACTN) No longer active
UCSD & City of Hope UCSD Cancer - Leukemia A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies Recruiting
UCSD
UCSD Stem Cell Clinic
(844) 317-7836
alphastemcellclinic@ucsd.edu
Persimmune, Inc. Cancer - Blood Collection of Bone Marrow, Peripheral Blood (PB), Epithelial Tissue, and Saliva Samples From Patients With Myelodysplastic Syndromes (MDS) to Identify MDS-Specific Antigens No longer active
UCSD Asterias Biotherapeutics Spinal Cord Injury Dose Escalation Study of AST-OPC1 in Spinal Cord Injury No longer active
UCSD Viacyte Diabetes - Type 1 Three Year Follow-up Safety Study in Subjects Previously Implanted With VC-01 Recruiting
UCSD UCSD Cancer - Leukemia Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961 No longer active
UCSD Neuralstem Spinal Cord Injury Safety Study of Human Spinal Cord-derived Neural Stem Cell Transplantation for the Treatment of Chronic SCI Recruiting
UCSD Viacyte Diabetes - Type 1 A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness Recruiting
UCSD Mesoblast Heart Failure The Purpose of This Study is to Evaluate the Efficacy and Safety of a Allogeneic Mesenchymal Precursor Cells (CEP-41750) for the Treatment of Chronic Heart Failure Recruiting
UCSD UCSD Cancer - Leukemia UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia No longer active
UCSD Viacyte Diabetes - Type 1 A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus Active, not recruiting

UCLA
Scott Nowicki, MD, PhD

Ignacio Baselga Carretero, PhD
310-206-2090
IBaselga@mednet.ucla.edu
UCLA Cancer - Solid Tumors Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a Myeloablative Conditioning Regimen, With Administration of Interleukin-2, in Patients With Advanced Malignancies Recruiting
UCLA
Lia Etheridge
(310-825-7174)
letheridge@mednet.ucla.edu
UCLA Cancer - Lung A Phase I trial of intratumoral administration of CCL21-gene modified dendritic cell (DC) combined with intravenous pembrolizumab for advanced NSCLC Recruiting
UCLA
Sarah Larson, MD
310-206-8477
slarson@mednet.ucla.edu
UCLA Cancer TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma (NYSCT MM) No longer active
UCLA
Maricela Gonzalez
(310) 557-3729
mmgonzalez@mednet.ucla.edu
Calimmune HIV/AIDS Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection No longer active
UCLA
Caroline Kuo, MD
310-794-1940
ckuo@mednet.ucla.edu
UCLA X-linked Chronic Granulomatous Disease Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease Recruiting
UCLA
Fabrizia Urbinati, PhD
(310) 794-1884
furbinati@ucla.edu
UCLA Sickle Cell Disease Stem Cell Gene Therapy for Sickle Cell Disease Recruiting
UCLA
Kit L Shaw, PhD
(310) 267-0584
kshaw@mednet.ucla.edu
UCLA Severe Combined Immunodeficiency (SCID) Autologous Transplant of EFS-ADA Modified Bone Marrow Cells for ADA-Deficient Severe Combined Immunodeficiency (SCID) No longer active
UCLA
Kit L Shaw, PhD
(310) 267-0584
kshaw@mednet.ucla.edu
Orchard Therapeutics Severe Combined Immunodeficiency (SCID) Efficacy and Safety of a Cryopreserved Formulation of Autologous CD34+ Hematopoietic Stem Cells Transduced Ex Vivo With EFS Lentiviral Vector Encoding for Human ADA Gene in Subjects With ADA Deficiency Severe Combined Immunodeficiency Active, not recruiting
1 2 3

Clinical trials conducted at CIRM Alpha Stem Cell Clinics must comply with applicable federal and state laws and medical and ethical standards governing the conduct of human clinical trials. If you or a family member is interested in participating in a clinical trial, please visit clinicaltrials.gov to find a trial near you.

Find Out More:
About Alpha Stem Cell Clinics
Alpha Clinics News